# US 2016/0216263 A1 · Porcine torque teno virus vaccines and diagnosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0216263 A1
- Document ID: US20160216263A1
- Status: Published application
- Kind: A1
- Application number: 14/946,384
- Filed: 2015-11-19
- Published: 2016-07-28
- Earliest claimed: 2009-08-21
- Assignees: Virginia Tech Intellectual Properties, Inc.
- Applicants: Virginia Tech Intellectual Properties, Inc.
- Inventors: Xiang-Jin MENG; Yaowei Huang
- Web page: https://patentgrep.com/patent/US20160216263A1

## CPC

- G01N 33/56983: {Viruses}
- A61K 39/12: Viral antigens
- A61P 31/20: for DNA viruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C07K 16/081: DNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/701: {Specific hybridization probes}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2750/00021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2750/14034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G01N 2333/01: DNA viruses
- G01N 2333/085: Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine Torque teno virus (PTTV) genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA. The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same. The present invention further provides live, attenuated, vector-expressed and purified recombinant capsid subunit or killed viral vaccines for protection against PTTV infection. The present invention additionally provides subunit vaccines comprising PTTV specific gene products, especially ORF1 capsid gene product for protection against PTTV infection. Further, the present invention provides methods for diagnosing PTTV infection via polymerase chain reaction (PCR) using specific primer for PTTV1, PTTV2, and individual PTTV1 genotypes. Finally, the present invention provides methods for diagnosing PTTV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies.

## Claims

### Claim 1

An infectious nucleic acid molecule of porcine Torque teno virus (PTTV) comprising a nucleic acid molecule encoding an infectious PTTV which contains at least one copy of genomic sequence having at least 85% homology to a genomic sequence selected from the group consisting of PTTV 1a-VA, PTTV 1b-VA, PTTV2b-VA, and PTTV2c-VA.

### Claim 2 (depends on 1)

The infectious nucleic acid molecule of claim 1, wherein the at least one copy of genomic sequence having at least 95% homology to the genomic sequence selected from the group consisting of PTTV 1a-VA, PTTV 1b-VA, PTTV2b-VA, and PTTV2c-VA.

### Claim 3 (depends on 1)

The infectious nucleic acid molecule of claim 1, wherein the genomic sequence is selected from sequences set forth in SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

### Claim 4 (depends on 3)

A biologically functional plasmid or viral vector containing the infectious nucleic acid molecule according to claim 3.

### Claim 5 (depends on 4)

The biologically functional plasmid or viral vector of claim 4, containing more than one copy of the infectious nucleic acid molecule.

### Claim 6 (depends on 4)

A suitable host cell transfected by the vector comprising the infectious nucleic acid molecule according to claim 4.

### Claim 7 (depends on 6)

An avirulent, infectious PTTV produced by cells containing the infectious nucleic acid molecule according to claim 6.

### Claim 8

A vaccine comprising a nontoxic, physiologically acceptable carrier and an immunogenic amount of a member selected from the group consisting of:
(a) a nucleic acid molecule containing at least one copy of genomic sequence having at least 80% homology to a genomic sequence selected from the group consisting of PTTV genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA, or its complementary strand;
(b) a biologically functional plasmid or viral vector containing a nucleic acid molecule containing at least one copy of genomic sequence having at least 80% homology to a genomic sequence selected from the group consisting of PTTV genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA, or its complementary strand;
(c) an avirulent, infectious nonpathogenic porcine Torque teno virus, which is derived from and contains a genomic sequence having at least 85% homology to a genomic sequence selected from the group consisting of PTTV genotypes or subtypes PTTV1a-VA, PTTV1b- VA, PTTV2b-VA, and PTTV2c-VA; and
(d) an immunogenic fragment of a polypeptide sequence or a complete protein translated according to a polynucleotide sequence selected from the group consisting of ORF1, ORF2, ORF1/1, and ORF2/2 of PTTV genotypes or subtypes PTTV1a-VA, PTTV1b- VA, PTTV2b-VA, and PTTV2c-VA.

### Claim 9 (depends on 8)

The vaccine according to claim 8, wherein the vaccine contains live PTTV virus.

### Claim 10 (depends on 8)

The vaccine according to claim 8, wherein the vaccine contains killed PTTV virus.

### Claim 11 (depends on 8)

The vaccine according to claim 8, wherein the immunogenic fragment of a polypeptide sequence or a complete protein comprising purified bacterial expressed or baculovirus-expressed recombinant proteins expressed from ORF1, ORF2, ORF1/1 and ORF2/2 of PTTV genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA.

### Claim 12 (depends on 11)

The vaccine according to claim 11, wherein the immunogenic fragment of a polypeptide sequence or a complete protein comprising purified bacterial expressed or baculovirus-expressed recombinant proteins expressed from ORF1 of PTTV genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA.

### Claim 13 (depends on 8)

The vaccine according to claim 8, further contains an adjuvant.

### Claim 14 (depends on 8)

A method of immunizing a pig against PTTV viral infection, comprising administering to a pig an immunologically effective amount of the vaccine according to claim 8.

### Claim 15 (depends on 14)

The method according to claim 14, which comprising administering the vaccine parenterally, intranasally, intradermally, or transdermally to the pig.

### Claim 16 (depends on 14)

The method according to claim 14, which comprising administering the vaccine intralymphoidly or intramuscularly to the pig.

### Claim 17

An isolated polynucleotide consisting of a poly nucleic acid sequence having 85% homology to a nucleotide sequence of PTTV1a-VA set forth in SEQ ID NO:9.

### Claim 18 (depends on 17)

The isolated polynucleotide of claim 17, wherein the poly nucleic acid sequence having 95% homology to the nucleotide sequence of PTTV1a-VA set forth in SEQ ID NO:9.

### Claim 19 (depends on 17)

The isolated polynucleotide of claim 17, wherein the poly nucleic acid sequence consisting the nucleotide sequence of PTTV1a-VA set forth in SEQ ID NO:9.

### Claim 20

An isolated polynucleotide consisting of a poly nucleic acid sequence having 85% homology to a nucleotide sequence of PTTV1b-VA set forth in SEQ ID NO: 10.

### Claim 21 (depends on 20)

The isolated polynucleotide of claim 20, wherein the poly nucleic acid sequence having 95% homology to the nucleotide sequence of PTTV1b-VA set forth in SEQ ID NO: 10.

### Claim 22 (depends on 20)

The isolated polynucleotide of claim 20, wherein the poly nucleic acid sequence consisting the nucleotide sequence of PTTV1b-VA set forth in SEQ ID NO: 10.

### Claim 23

An isolated polynucleotide consisting of a poly nucleic acid sequence having 85% homology to a nucleotide sequence of PTTV2b-VA set forth in SEQ ID NO: 11.

### Claim 24 (depends on 23)

The isolated polynucleotide of claim 23, wherein the poly nucleic acid sequence having 95% homology to the nucleotide sequence of PTTV2b-VA set forth in SEQ ID NO: 11.

### Claim 25 (depends on 23)

The isolated polynucleotide of claim 23, wherein the poly nucleic acid sequence consisting the nucleotide sequence of PTTV2b-VA set forth in SEQ ID NO: 11.

### Claim 26

An isolated polynucleotide consisting of a poly nucleic acid sequence having 85% homology to a nucleotide sequence of PTTV2c-VA set forth in SEQ ID NO: 12.

### Claim 27 (depends on 23)

The isolated polynucleotide of claim 23, wherein the poly nucleic acid sequence having 95% homology to the nucleotide sequence of PTTV2c-VA set forth in SEQ ID NO: 12.

### Claim 28 (depends on 23)

The isolated polynucleotide of claim 23, wherein the poly nucleic acid sequence consisting the nucleotide sequence of PTTV2c-VA set forth in SEQ ID NO: 12.

### Claim 29

A vaccine comprising an immunogentic fragment of a polypeptide sequence or a complete protein translated according to a polynucleotide sequence selected from the group consisting of ORF1, ORF2, ORF1/1, and ORF2/2 of PTTV genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA.

### Claim 30 (depends on 29)

The vaccine of claim 29, wherein the immunogenic fragment or complete protein is a capsid protein of PTTV genotypes or subtypes PTTV 1a-VA, PTTV 1b-VA, PTTV2b-VA, and PTTV2c-VA.

### Claim 31 (depends on 29)

The vaccine of claim 29, wherein the polynucleotide sequence is selected from the group consisting of ORF1 of PTTV genotypes or subtypes PTTV1a-VA, PTTV 1b-VA, PTTV2b- VA, and PTTV2c-VA.

### Claim 32 (depends on 31)

The vaccine of claim 31, wherein the polynucleotide sequence is ORF1 of PTTV genotype PTTV1 a-VA.

### Claim 33 (depends on 31)

The vaccine of claim 31, wherein the polynucleotide sequence is ORF1 of PTTV genotype PTTV1b-VA.

### Claim 34 (depends on 31)

The vaccine of claim 31, wherein the polynucleotide sequence is ORF1 of PTTV subtype PTTV2c-VA.

### Claim 35 (depends on 29)

The vaccine of claim 29, wherein the polypeptide sequence is selected from the group consisting of sequence set forth in SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17, SEQ ID No:18, SEQ ID No:19, SEQ ID No:20, SEQ ID No:21, SEQ ID No:22, SEQ ID No:23, SEQ ID No:24, SEQ ID No:25, SEQ ID No:26, SEQ ID No:27, and SEQ ID No:28.

### Claim 36 (depends on 35)

The vaccine of claim 35, wherein the polypeptide sequence is set forth in SEQ ID No:13.

### Claim 37 (depends on 36)

The vaccine of claim 36, wherein the polypeptide sequence is a C-terminal region (aa 317-635) of SEQ ID No:13.

### Claim 38 (depends on 35)

The vaccine of claim 35, wherein the polypeptide sequence is set forth in SEQ ID No:14.

### Claim 39 (depends on 38)

The vaccine of claim 38, wherein the polypeptide sequence is a C-terminal region (aa 322-639) of SEQ ID No:14.

### Claim 40 (depends on 35)

The vaccine of claim 35, wherein the polypeptide sequence is set forth in SEQ ID No:16.

### Claim 41 (depends on 40)

The vaccine of claim 40, wherein the polypeptide sequence is C-terminal region (aa 310-625) of SEQ ID No:16.

### Claim 42 (depends on 35)

The vaccine of claim 35, wherein the polypeptide sequence is set forth in SEQ ID No:20.

### Claim 43 (depends on 29)

The vaccine according to claim 29, further contains an adjuvant.

### Claim 44 (depends on 29)

A method of immunizing a pig against PTTV viral infection, comprising administering to a pig an immunologically effective amount of the vaccine according to claim 29.

### Claim 45 (depends on 44)

The method according to claim 44, which comprises administering the immunogentic fragment or complete protein to a pig.

### Claim 46 (depends on 44)

The method according to claim 44, which comprises administering the vaccine parenterally, intranasally, intradermally, or transdermally to the pig.

### Claim 47 (depends on 44)

The method according to claim 44, which comprises administering the vaccine intralymphoidly or intramuscularly to the pig.

### Claim 48

A method for diagnosing PTTV1 infection and quantification of PTTV1 load, comprising:
extracting DNA from a sample suspected of PTTV1 infection;
performing polymerase chain reaction (PCR) using primers comprising the sequences set forth in SEQ ID NO:29 and SEQ ID NO:30; and
detecting PTTV1 specific amplification.

### Claim 49 (depends on 48)

The method of claim 48, wherein the polymerase chain reaction is a SYBR green realtime PCR.

### Claim 50

A method for diagnosing PTTV2 infection and quantification of PTTV2 load, comprising:
extracting DNA from a sample suspected of PTTV2 infection;
performing polymerase chain reaction (PCR) using primers comprising the sequences set forth in SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32; and
detecting PTTV2 specific amplification.

### Claim 51 (depends on 50)

The method of claim 50, wherein the polymerase chain reaction is a SYBR green realtime PCR.

### Claim 52

A method for simultaneously detecting and diagnosing PTTV1 and PTTV2 infection, comprising:
extracting DNA from a sample suspected of PTTV infection;
performing polymerase chain reaction (PCR) using primers comprising the sequences set forth in SEQ ID NO:31 and SEQ ID NO:32; and
detecting PTTV1 and PTTV2 specific amplification.

### Claim 53 (depends on 52)

The method of claim 52, wherein the polymerase chain reaction is a SYBR green realtime PCR.

### Claim 54

A method for simultaneously detecting and diagnosing PTTV1a and PTTV1b infection, comprising:
extracting DNA from a sample suspected of PTTV1 infection;
performing a first polymerase chain reaction (PCR) using primers comprising the sequences set forth in SEQ ID NO:33 and SEQ ID NO:34;
performing a second PCR using primers comprising the sequences set forth in SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, and SEQ ID NO:38; and
detecting PTTV1a and PTTV1b specific amplification.

### Claim 55

A method for diagnosing PTTV infection, comprising
immobilizing an immunogentic fragment or a complete protein of a polypeptide sequence translated according to a polynucleotide sequence selected from the group consisting of ORF1, ORF2, ORF1/1, and ORF2/2 of PTTV subtypes PTTV1a-VA, PTTV1b- VA, PTTV2b-VA, and PTTV2c-VA;
contacting a serum sample from a pig suspected of PTTV infection with the immobilized immunogentic fragment or complete protein; and
detecting captured antibody specific to the immunogentic fragment.

### Claim 56

The method of 55, wherein the polynucleotide sequence is selected from the group consisting of ORF1 of PTTV genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b- VA, and PTTV2c-VA.

### Claim 57 (depends on 56)

The vaccine of claim 56, wherein the polynucleotide sequence is ORF1 of PTTV genotype PTTV1 a-VA.

### Claim 58 (depends on 56)

The method of claim 56, wherein the polynucleotide sequence is ORF1 of PTTV genotype PTTV1b-VA.

### Claim 59 (depends on 56)

The method of claim 56, wherein the polynucleotide sequence is ORF1 of PTTV subtype PTTV2c-VA.

### Claim 60 (depends on 55)

The method of claim 55, wherein the polypeptide sequence is selected from the group consisting of sequence set forth in SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17, SEQ ID No:18, SEQ ID No:19, SEQ ID No:20, SEQ ID No:21, SEQ ID No:22, SEQ ID No:23, SEQ ID No:24, SEQ ID No:25, SEQ ID No:26, SEQ ID No:27, and SEQ ID No:28.

### Claim 61 (depends on 60)

The method of claim 60, wherein the polypeptide sequence is set forth in SEQ ID No:13.

### Claim 62 (depends on 60)

The vaccine of claim 60, wherein the polypeptide sequence is set forth in SEQ ID No:16.

### Claim 63 (depends on 62)

The vaccine of claim 62, wherein the immunogentic fragment is C-terminal region (aa 317-635) of SEQ ID No:13, (aa 322-639) of SEQ ID No:14, or (aa 3 10-625) of SEQ ID No:16.

### Claim 64 (depends on 60)

The vaccine of claim 60, wherein the polypeptide sequence is set forth in SEQ ID No:20.

### Claim 65 (depends on 55)

The method of claim 55, wherein the detecting captured antibody is via Western blot.

### Claim 66 (depends on 55)

The method of claim 55, wherein the detecting captured antibody is via enzyme-linked immunosorbent assay (ELISA).
